End-to-End Multi-task Learning Architecture for Brain Tumor Analysis with Uncertainty Estimation in MRI Images

Abstract

Brain tumors are a threat to life for every other human being, be it adults or children. Gliomas are one of the deadliest brain tumors with an extremely difficult diagnosis. The reason is their complex and heterogenous structure which gives rise to subjective as well as objective errors. Their manual segmentation is a laborious task due to their complex structure and irregular appearance. To cater to all these issues, a lot of research has been done and is going on to develop AI-based solutions that can help doctors and radiologists in the effective diagnosis of gliomas with the least subjective and objective errors, but an end-to-end system is still missing. An all-in-one framework has been proposed in this research. The developed end-to-end multi-task learning (MTL) architecture with a feature attention module can classify, segment, and predict the overall survival of gliomas by leveraging task relationships between similar tasks. Uncertainty estimation has also been incorporated into the framework to enhance the confidence level of healthcare practitioners. Extensive experimentation was performed by using combinations of MRI sequences. Brain tumor segmentation (BraTS) challenge datasets of 2019 and 2020 were used for experimental purposes. Results of the best model with four sequences show 95.1% accuracy for classification, 86.3% dice score for segmentation, and a mean absolute error (MAE) of 456.59 for survival prediction on the test data. It is evident from the results that deep learning–based MTL models have the potential to automate the whole brain tumor analysis process and give efficient results with least inference time without human intervention. Uncertainty quantification confirms the idea that more data can improve the generalization ability and in turn can produce more accurate results with less uncertainty. The proposed model has the potential to be utilized in a clinical setup for the initial screening of glioma patients.